Combining NMR and X-ray crystallography in fragment-based drug discovery: Discovery of highly potent and selective BACE-1 inhibitors

Topics in Current Chemistry

Volumn 317, Issue , 2012, Pages 83-114

  Wyss, Daniel F ^a   Wang, Yu Sen ^a   Eaton, Hugh L ^a   Strickland, Corey ^a   Voigt, Johannes H ^a   Zhu, Zhaoning ^a   Stamford, Andrew W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alzheimer's disease; Aspartic acid protease; BACE 1; Fragment based drug discovery; Structure based design

Indexed keywords

ENZYME INHIBITOR; SECRETASE;

CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DEVELOPMENT; HIGH THROUGHPUT SCREENING; METABOLISM; MOLECULAR LIBRARY; NUCLEAR MAGNETIC RESONANCE; REVIEW; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

AMYLOID PRECURSOR PROTEIN SECRETASES; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; MODELS, MOLECULAR; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84863242691     PISSN: 03401022     EISSN: None     Source Type: Book Series    
DOI: 10.1007/128-2011-183     Document Type: Review

References (115)

1. Jahnke W, Erlanson DA (eds) (2006) Fragment-based approaches in drug discovery. In: Mannhold R, Kubinyi H, Folkers G (series eds) Methods and principles in medicinal chemistry, Vol 34. Wiley-VCH, Weinheim, Germany
2. Zartler ER, Shapiro MJ (eds) (2008) Fragment-based drug discovery: a practical approach. Wiley, Chichester, UK
3. Rees DC, Congreve M, Murray CW, Carr R (2004) Fragment-based lead discovery. Nat Rev Drug Discov 3:660-672 (Pubitemid 39173507)
4. Erlanson DA, McDowell RS, O'Brien T (2004) Fragment-based drug discovery. J Med Chem 47:3463-3482 (Pubitemid 38822007)
5. Erlanson DA (2006) Fragment-based lead discovery: a chemical update. Curr Opin Biotechnol 17:643-652 (Pubitemid 44791912)
6. Hajduk PJ, Greer J (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6:211-2197.
7. Wyss DF, Eaton HL (2007) Fragment-based approaches to lead discovery. Front Drug Des Discov 3:171-202
8. Alex AA, Flocco MM (2007) Fragment-based drug discovery: what has it achieved so far? Curr Top Med Chem 7:1544-1567 (Pubitemid 350131014)
9. Congreve M, Chessari G, Tisi D, Woodhead AJ (2008) Recent developments in fragmentbased drug discovery. J Med Chem 51:3661-3680 (Pubitemid 351956496)
10. de Kloe GE, Bailey D, Leurs R, de Esch IJP (2009) Transforming fragments into candidates: small becomes big in medicinal chemistry. Drug Discov Today 14:630-646
11. Chessari G, Woodhead AJ (2009) From fragment to clinical candidate-a historical perspective. Drug Discov Today 14:668-675
12. Murray CW, Rees DC (2009) The rise of fragment-based drug discovery. Nat Chem 1:187-192
13. Schulz MN, Hubbard RE (2009) Recent progress in fragment-based lead discovery. Curr Opin Pharm 9:615-621
14. Murray CW, Blundell TL (2010) Structural biology in fragment-based drug design. Curr Opin Struct Biol 20:497-507
15. Gozalbes R, Carbajo RJ, Pineda-Lucena A (2010) Contributions of computational chemistry and biophysical techniques to fragment-based drug discovery. Curr Med Chem 17:1769-1794
16. Fink T, Bruggesser H, Reymond JL (2005) Virtual exploration of the small-molecule chemical universe below 160 Daltons. Angew Chem Int Ed Engl 44:1504-1508 (Pubitemid 40460043)
17. Fink T, Reymond JL (2007) Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery. J Chem Inf Model 47:342-353 (Pubitemid 46615939)
18. Hann MM, Leach RL, Harper G (2001) Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci 41:856-864
19. Coyne AG, Scott DE, Abell C (2010) Drugging challenging targets using fragment-based approaches. Curr Opin Chem Biol 14:299-307
20. Congreve M, Carr R, Murray CW, Jhoti H (2003) A 'rule of three' for fragment-based lead discovery? Drug Discov Today 8:876-877 (Pubitemid 37194496)
21. Hopkins AL, Groom CR, Alex A (2004) Ligand efficiency: a useful metric for lead selection. Drug Discov Today 9:430-431 (Pubitemid 38510559)
22. Abad-Zapatero C, Metz JT (2005) Ligand efficiency indices as guideposts for drug discovery. Drug Discov Today 10:464-469
23. Verdonk ML, Rees DC (2008) Group efficiency: a guideline for hits-to-leads chemistry. ChemMedChem 3:1179-1180
24. Reynolds CH, Bembenek SD, Tounge BA (2007) The role of molecular size in ligand efficiency. Bioorg Med Chem Lett 42:4258-4261 (Pubitemid 47028600)
25. Reynolds CH, Tounge BA, Bembenek SD (2008) Ligand binding efficiency: trends, physical basis, and implications. J Med Chem 51:2432-2438 (Pubitemid 351628504)
26. Bembenek SD, Tounge BA, Reynolds CH (2009) Ligand efficiency and fragment-based drug discovery. Drug Discov Today 14:278-283
27. Nissink JWM (2009) Simple size-independent measure of ligand efficiency. J Chem Inf Model 49:1617-1622
28. Orita M, Ohno K, Niimi T (2009) Two 'golden ratio' indices in fragment-based drug discovery. Drug Discov Today 14:321-328
29. Leeson PD, Springthorpe B (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6:881-890 (Pubitemid 350042396)
30. Keseru GM, Makara GM (2009) The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 8:203-212
31. Hajduk PJ (2006) Fragment-based drug design: how big is too big? J Med Chem 49:6972-6976 (Pubitemid 44885985)
32. Perola E (2010) An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. J Med Chem 53:2986-2997
33. Abad-Zapatero C, Perisic O, Wass J, Bento AP, Overington J, Al-Lazikani B, Johnson ME (2010) Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. Drug Discov Today 15:804-811
34. Schultes S, de Graaf C, Haaksma EEJ, de Esch IJP, Leurs R, Kramer O (2010) Ligand efficiency as a guide in fragment hit selection and optimization. Drug Discov Today Technol 7:e157-e162
35. Ferenczy GG, Keseru GM (2010) Thermodynamics guided lead discovery and optimization. Drug Discov Today 15:919-932
36. Ladbury JE, Klebe G, Freire E (2010) Adding calorimetric data to decision making in lead discovery: a hot tip. Nat Rev Drug Discov 9:23-27
37. Teague SJ et al (1999) The design of lead like combinatorial libraries. Angew Chem Int Ed Engl 38:3743-3748 (Pubitemid 30022004)
38. Oprea TI et al (2001) Is there a difference between leads and drugs? A historical perspective. J Chem Inf Comput Sci 41:1308-1315
39. Hann MM, Oprea TI (2004) Pursuing the leadlikeness concept in pharmaceutical research. Curr Opin Chem Biol 8:255-263 (Pubitemid 38759400)
40. Dalvit C (2009) NMR methods in fragment screening: theory and a comparison with other biophysical techniques. Drug Discov Today 14:1051-1057
41. Retra K, Irth H, Muijlwijk-Koezen JE (2010) Surface plasmon resonance biosensor analysis as a useful tool in FBDD. Drug Discov Today Technol 7:e181-e187
42. Jhoti H, Cleasby A, Verdonk M, Williams G (2007) Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr Opin Chem Biol 11:485-493 (Pubitemid 47588996)
43. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW (1996) Discovering high affinity ligands for proteins: SAR by NMR. Science 274:1531-1534 (Pubitemid 26403929)
44. Hajduk PJ, Augeri DJ, Mack J, Mendoza R, Yang J, Betz SF, Fesik SW (2000) NMR-based screening of proteins containing 13 C-labeled methyl groups. J Am Chem Soc 122:7898-7904 (Pubitemid 30659411)
45. Mayer M, Meyer B (2001) Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc 123:6108-6117 (Pubitemid 32888480)
46. Wang YS, Liu D, Wyss DF (2004) Competition STD NMR for the detection of high-affinity ligands and NMR-based screening. Magn Reson Chem 42:485-499
47. McCoy MA, Senior MM, Wyss DF (2005) Screening of protein kinases by ATP-STD NMR spectroscopy. J Am Chem Soc 127:7978-7979 (Pubitemid 40799628)
48. Dalvit C (2008) Theoretical analysis of the competition ligand-based NMR experiments and selected applications to fragment screening and binding constant measurements. Concepts Magn Reson A 32A:341-372
49. Dalvit C, Ardini E, Flocco M, Fogliatto GP, Mongelli N, VeronesiM(2003) A general NMR method for rapid, efficient, and reliable biochemical screening. J Am Chem Soc 125:14620-14625 (Pubitemid 37452398)
50. Jacoby E, Davies J, Blommers MJ (2003) Design of small molecule libraries for NMR screening and other applications in drug discovery. Curr Top Med Chem 3:11-23
51. Baurin N, Aboul-Ela F, Barril X, Davis B, Drysdale M, Dymock B, Finch H, Fromont C, Richardson C, Simmonite H, Hubbard RE (2004) Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets. J Chem Inf Comput Sci 44:2157-2166
52. Blomberg N, Cosgrove DA, Kenny PW, Kolmodin K (2009) Design of compound libraries for fragment screening. J Comput Aided Mol Des 23:513-525
53. Chen IJ, Hubbard RE (2009) Lessons for fragment library design: analysis of output from multiple screening campaigns. J Comput Aided Mol Des 23:603-620
54. Boyd SM, de Kloe GE (2010) Fragment library design: efficiently hunting drugs in chemical space. Drug Discov Today Technol 7:e173-e180.
55. Gleeson MP (2008) Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem 51:817-834 (Pubitemid 351304691)
56. Wenlock MC, Austin RP, Barton P, Davis AM, Leeson PD (2003) A comparison of physicochemical property profiles of development and marketed oral drugs. J Med Chem 46:1250-1256 (Pubitemid 36428230)
57. Mortenson PN, Murray CW (2009) Ligand lipophilicity efficiency-assessing lipophilicity of fragments and early hits. Presented at RSC Fragments 2009, Astra Zeneca Alderley Park, UK, 4-5 March 2009, Poster 9
58. Freire E (2008) Do enthalpy and entropy distinguish first in class from best in class? Drug Discov Today 13:869-874
59. Scott AD, Phillips C, Alex A, Flocco M, Bent A, Randall A, O'Brien R, Damian L, Jones LH (2009) Thermodynamic optimisation in drug discovery: a case study using carbonic anhydrase inhibitors. ChemMedChem 4:1985-1989
60. Ward HJ, Holdgate GA (2001) Isothermal titration calorimetry in drug discovery. Prog Med Chem 38:309-376
61. Chung S, Parker JB, Bianchet M, Amzel LM, Stivers JT (2009) Impact of linker strain and flexibility in the design of a fragment-based inhibitor. Nat Chem Biol 5:407-413
62. Barelier S, Pons J, Marcillat O, Lancelin J-M, Krimm I (2010) Fragment-based deconstruction of Bcl-xL inhibitors. J Med Chem 53:2577-2588
63. Ji H, Li H, Martasek P, Roman LJ, Poulos TL, Silverman RB (2009) Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping. J Med Chem 52:779-797
64. Levy-Lehad E, Wijsman E, Nemens E, Anderson A, Goddard KA, Weber JL (1995) A familial Alzheimer's disease locus on chromosome 1. Science 269:970-973
65. Melnikova I (2007) Therapies for Alzheimer's disease. Nat Rev Drug Discov 6:341-342 (Pubitemid 46696548)
66. Mount C, Downton C (2006) Alzheimer disease: progress or profit? Nat Med 12:780-784 (Pubitemid 44050066)
67. Moreira PI, Zhu X, Nunomura A, Smith MA, Perry G (2006) Therapeutic options in Alzheimer's disease. Expert Rev Neurother 6:897-910 (Pubitemid 43961890)
68. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356 (Pubitemid 34790756)
69. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid b-peptide. Nat Rev Mol Cell Biol 8:101-112 (Pubitemid 46432529)
70. Korczyn AD (2008) The amyloid cascade hypothesis. Alzheimers Dement 4:176-178 (Pubitemid 351682258)
71. Hardy J (2006) Has the amyloid cascade hypothesis for Alzheimer's been proved? Curr Alzheimer Res 3:71-73
72. Selkoe D (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-766 (Pubitemid 32267077)
73. Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T (2006) Amyloid load and cerebral atrophy in Alzheimer's disease: a 11 C-BIP positron emission tomography study. Ann Neurol 60:145-147
74. Olson MI, Shaw CM (1969) Presenile dementia and Alzheimer's disease in mongolism. Brain 92:147-156
75. Mann DMA (1998) Alzheimer's disease and Down's syndrome. Histopathology 13:125-137
76. Prasher VP, Farrer MJ, Kessling AM, Fisher EMC, West RJ, Barber SPC, Butler AC (1998) Molecular mapping of IIv Alzheimer-type dementia in Down's syndrome. Ann Neurol 43:380-383 (Pubitemid 28113601)
77. Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW (1991) In vitro aging of amyloid-beta protein causes peptide aggregation and neurotoxicity. Brain Res 573:311-314
78. Lorenzo A, Yankner B (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci USA 91:12243-12247 (Pubitemid 24368641)
79. Iversen LL, Mortishire-Sith RJ, Pollack SJ, Shearman MS (1995) The toxicity in vitro of beta-amyloid protein. Biochem J 311:1-16
80. Tsai J, Grutzendler J, Duff K, Gan W (2004) Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci 7:1181-1183 (Pubitemid 39426234)
81. Mor F, Monsonego A (2006) Immunization therapy in Alzheimer's disease. Expert Rev Neurother 6:653-659 (Pubitemid 43961870)
82. Qu B, Boyer PJ, Johnston SA, Hynan LS, Rosenberg RN (2006) Ab42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J Neurol Sci 244:151-158
83. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L (2005) Evaluation of the safety and immunogenicity of syntheticAb42 (AN1792) in patients with AD. Neurology 64:94-101 (Pubitemid 40082943)
84. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC (2005) Clinical effects of Ab immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553-1562 (Pubitemid 40617691)
85. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tilmanns B (2003) Antibodies against b-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38:547-554 (Pubitemid 36645030)
86. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L (2005) Effects of Ab immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64:1563-1572 (Pubitemid 40617692)
87. DaSilva KA, Aubert I, McLaurin J (2006) Vaccine development for Alzheimer's disease. Curr Pharm Des 12:4283-4293 (Pubitemid 44718291)
88. Hussain I, Powell D, Howlett DR, Tew DG, Meek TD, Chapman C, Gloger IS, Murphy KE, Southan CD, Ryan DM, Smith TS, Simmons DL, Walsh FS, Dingwall C, Christie G (1999) Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 14:419-427 (Pubitemid 30026585)
89. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D (1999) Purification and cloning of amyloid precursor protein beta secretase from human brain. Nature 402:537-540
90. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735-741
91. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL, Gurney ME (1999) Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402:533-537
92. Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H (2000) BACE2, a beta-secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc Natl Acad Sci USA 97:9712-9717 (Pubitemid 30650841)
93. Saunders AJ, Kim T-M, Tanzi RE (1999) BACE maps to chromosome 11 and a BACE homolog, BACE2, reside in the obligate Down syndrome region of chromosome 21. Science 286:1255a
94. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, Fan W, Kha H, Zhang J, Gong Y, Martin L, Louis JC, Yan Q, Richards WG, Citron M, Vassar R (2001) Mice deficient in BACE1, the Alzheimer's beta secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4:231-232 (Pubitemid 32194866)
95. Luo Y, Bolon B, Damore MA, Fitzpatrick D, Liu H, Zhang J, Yan Q, Vassar R, Citron M (2003) BACE1 (beta secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol Dis 14:81-88 (Pubitemid 37103182)
96. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C (2006) Control of peripheral nerve myelination by the b-secretase BACE1. Science 314:664-666 (Pubitemid 44646394)
97. Wang H, Song L, Laird F, Wong PC, Lee H-K (2008) BACE1 knock-outs display deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus. J Neurosci 28:8677-8681
98. Ohno M, Sametsky EA, Younkin LH, Oakley H, Younkin SG, Citron M, Vassar R, Disterhoft JF (2004) BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41:27-33 (Pubitemid 38071826)
99. Ghosh AK, Shin D, Downs D, Koelsch G, Lin X, Ermolieff J, Tang J (2000) Design of potent inhibitors for human brain memapsin 2 (b-secretase). J Am Chem Soc 122:3522-3523 (Pubitemid 30211128)
100. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC, Tang J (2000) Structure of the protease domain of memapsin 2 (b-secretase) complexed with inhibitor. Science 290:150-153
101. Stachel SJ (2009) Progress toward the development of a viable BACE-1 inhibitor. Drug Dev Res 70:101-110
102. Durham TB, Shepherd TA (2006) Progress toward the discovery and development of efficacious BACE inhibitors. Curr Opin Drug Discov Dev 9:776-791 (Pubitemid 44759568)
103. Maillard MC, Hom RK, Benson TE, Moon JB, Mamo S, Bienkowski M, Tomasselli AG, Woods DD, Prince DB, Paddock DJ, Emmons TL, Tucker JA, Dappen MS, Brogley L, Thorsett ED, Jewett N, Sinha S, Varghese J (2007) Design, synthesis, and crystal structure of hydroxyethyl secondary amine-based peptidomimetic inhibitors of human beta-secretase. J Med Chem 50:776-781 (Pubitemid 46332990)
104. Wang YS, Strickland C, Voigt JH, Kennedy ME, Beyer BM, Senior MM, Smith EM, Nechuta TL, Madison VS, Czarniecki M, McKittrick BA, Stamford AW, Parker EM, Hunter JC, Greenlee WJ, Wyss DF (2010) Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel mM leads for the development of nM BACE-1 (b-site APP cleaving enzyme 1) inhibitors. J Med Chem 53:942-950
105. Zhu Z, Sun ZY, Ye Y, Voigt J, Strickland C, Smith EM, Cumming J, Wang L, Wong J, Wang YS, Wyss DF, Chen X, Kuvelkar R, Kennedy ME, Favreau L, Parker E, McKittrick BA, Stamford A, Czarniecki M, Greenlee W, Hunter JC (2010) Discovery of cyclic acylguanidines as highly potent and selective b-site amyloid cleaving enzyme (BACE) inhibitors: part I-inhibitor design and validation. J Med Chem 53:951-965
106. Geschwindner S, Olsson LL, Albert JS, Deinum J, Edwards PD, de Beer T, Folmer RH (2007) Discovery of a novel warhead against b-secretase through fragment-based lead generation. J Med Chem 50:5903-5911
107. Kuglstatter A, Stahl M, Peters JU, Huber W, Stihle M, Schlatter D, Benz J, Ruf A, Roth D, Enderle T, HennigM(2008) Tyramine fragment binding to BACE-1. Bioorg Med Chem Lett 18:1304-1307 (Pubitemid 351233037)
108. Murray CW, Callaghan O, Chessari G, Cleasby A, Congreve M, Frederickson M, Hartshorn MJ, McMenamin R, Patel S, Wallis N (2007) Application of fragment screening by X-ray crystallography to b-secretase. J Med Chem 50:1116-1123 (Pubitemid 46496312)
109. Congreve M, Aharony D, Albert J, Callaghan O, Campbell J, Carr RA, Chessari G, Cowan S, Edwards PD, Frederickson M, McMenamin R, Murray CW, Patel S, Wallis N (2007) Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of b-secretase. J Med Chem 50:1124-1132 (Pubitemid 46496313)
110. Edwards PD, Albert JS, Sylvester M, Aharony D, Andisik D, Callaghan O, Campbell JB, Carr RA, Chessari G, Congreve M, Frederickson M, Folmer RH, Geschwindner S, Koether G, Kolmodin K, Krumrine J, Mauger RC, Murray CW, Olsson LL, Patel S, Spear N, Tian G (2007) Application of fragment-based lead generation to the discovery of novel, cyclic amidine b-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. J Med Chem 50:5912-5925
111. Yang W, Fucini RV, Fahr BT, Randal M, Lind KE, Lam MB, Lu W, Lu Y, Cary DR, Romanowski MJ, Colussi D, Pietrak B, Allison TJ, Munshi SK, Penny DM, Pham P, Sun J, Thomas AE, Wilkinson JM, Jacobs JW, McDowell RS, Ballinger MD (2009) Fragmentbased discovery of nonpeptidic BACE-1 inhibitors using tethering. Biochemistry 48: 4488-4496112. Godemann R, Madden J, Kramer J, Smith M, Fritz U, Hesterkamp T, Barker J, Hoppner S, Hallett D, Cesura A, Ebneth A, Kemp J (2009) Fragment-based discovery of BACE1 inhibitors using functional assays. Biochemistry 48:10743-10751
112. Madden J, Dod JR, Godemann R, Kraemer J, Smith M, Biniszkiewicz M, Hallett DJ, Barker J, Dyekjaer JD, Hesterkamp T (2010) Fragment-based discovery and optimization of BACE1 inhibitors. Bioorg Med Chem Lett 20:5329-5333
113. Wang Y-S, Beyer BM, Senior MM, Wyss DF (2005) Characterization of autocatalytic conversion of precursor BACE1 by heteronuclear NMR spectroscopy. Biochemistry 44:16594-16601 (Pubitemid 41832041)
114. Liu D, Wang Y-S, Gesell JJ, Wilson E, Beyer BM, Wyss DF (2004) Backbone resonance assignments of the 45.3 kDa catalytic domain of human BACE1. J Biomol NMR 29:425-426 (Pubitemid 38864850)
115. Stamford A (2010) Discovery of small molecule, orally active and brain penetrant BACE1 inhibitors. Paper presented at 239th ACS National Meeting, San Francisco, CA, 21-25 March 2010